|View printer-friendly version|
Known as the “birthplace of American Medicine,” the
To become a Fellow, the inductee must be regarded as “a learned and dedicated physician, scientist, scholar, practitioner, or provider motivated by the interests of their patients, students and the public.”
Dr. Knowlton is the Co-founder, President, and Chief Marketing/New Business Development Officer for
Prior to TRHC, Dr. Knowlton was a key member of the start-up management team of excelleRx, a hospice medication management and pharmacy distribution company. During her tenure as Vice President, Chief Marketing, Strategy and Business Development Officer, from 1995 – 2007, the Company grew to service over 85,000 hospice patients in 49 states. The Company was purchased by a Fortune 500 company in 2005.
Dr. Knowlton has published widely, including papers, book chapters and articles. She co-authored the first published consensus guidelines on the standards for anticoagulation management centers, in conjunction with the
Active in the
Dr. Knowlton received her Bachelor of Science in Pharmacy and Doctorate in Pharmacy from the
TRHC (NASDAQ:TRHC) is a leader in providing patient-specific, data-driven technology and solutions that enable healthcare organizations to optimize medication regimens to improve patient outcomes, reduce hospitalizations, lower healthcare costs and manage risk. TRHC provides solutions for a range of payers, providers and other healthcare organizations. For more information, visit TRHC.com.
This press release includes forward-looking statements that we believe to be reasonable as of today’s date. Such statements are identified by use of the words “anticipates,” “believes,” “estimates,” “expects,” “intends,” “plans,” “predicts,” “projects,” “should,” and similar expressions. These forward-looking statements are based on management’s expectations and assumptions as of the date of this press release. Actual results might differ materially from those explicit or implicit in the forward-looking statements. Important factors that could cause actual results to differ materially include: the need to innovate and provide useful products and services; risks related to changing healthcare and other applicable regulations; increasing consolidation in the healthcare industry; managing our growth effectively; our ability to adequately protect our intellectual property; and the other risk factors set forth from time to time in our filings with the
|Dianne Semingson||Bob East or Asher Dewhurst|
|T: 215-870-0829||T: 443-213-0500|